The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia
Open accessAbstract
Sum m a r yHypoxia-inducible factors are transcription factors controlling energy, iron metabolism, erythropoiesis, and development.When these proteins are dysregulated, they contribute to tumorigenesis and cancer progression.However, mutations in genes encoding α subunits of hypoxia-inducible factors (HIF-α) have not previously been identified in any cancer.Here we report two novel somatic gain-of-function mutations in the gene encoding hypoxia-inducible factor 2α (HIF2A) in two patients, one presenting with paraganglioma and the other with paraganglioma and somatostatinoma, both of whom had polycythemia.The two mutations were associated with increased HIF-2α activity and increased protein half-life.H ypoxia-inducible factors, originally described by Wang et al., 1 are transcription factors that respond to changes in tissue oxygen concentration.These highly conserved proteins are composed of α and β subunits.The HIF-β subunit is constitutively expressed, whereas the α subunits are inducible by hypoxia and are associated with aggressive, treatment-refractory tumors.2,3 Under normoxic conditions, HIF-1α, HIF-2α, and HIF-3α are hydroxylated on specific prolyl residues, allowing for recognition by the von Hippel-Lindau (VHL) tumorsuppressor protein, ubiquitination, and rapid degradation through the proteasome.4 Under hypoxic conditions, prolyl hydroxylation of HIF-α proteins is reduced, resulting in their stabilization and, in turn, transcription of genes involved in the hypoxia response, including angiogenesis, glycolysis, apoptosis, proliferation, and growth.5,6 Paragangliomas and pheochromocytomas are catecholamine-producing tumors derived from the chromaffin cells of extraadrenal paraganglia and the adrenal medulla.7 The pioneering work of Neumann et al. 8 showed that about one fourth of these tumors were hereditary, a fraction that was subsequently estimated to be closer to one third, on the basis of the identification of mutations in several additional genes, including SDHA, SDHAF2, TMEM127, and MAX. 9 The identification of these genetic drivers led to the demonstration of HIF-α stabilization and dysregulation in paragangliomas and pheochromocytomas harboring mutations in VHL and succinate dehydrogenase (SDH).10,11 Somatostatinomas are somatostatin-producing neuroendocrine tumors believed to originate from neural-crest cells.They are occasionally diagnosed in patients with the VHL syndrome, multiple endocrine neoplasia type 1 or 2, or neurofibromatosis type 1. 12
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Somatic gain-of-function mutations in HIF2A have been discovered in pheochromocytomas and paragangliomas (Zhuang et al., 2012;Comino-Mendez et al., 2013;Lorenzo et al., 2013;Taieb et al., 2013;Toledo et al., 2013;Yang et al., 2013), while high HIF-2α expression is associated with poor survival in patients with neuroblastoma (Holmquist-Mengelbier et al., 2006).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Zhuang et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Lenders, J. W. M., Eisenhofer, G., Mannelli, M., & Pacák, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,541
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,350
Flagged first, then by citations
Research works printed but not linked: 3
- Vinik AI, 1987, Semin Oncol, 14, 263
- Morris MR, 2009, Anticancer Res, 29, 4337
- Prchal JT, 2008, N Engl J Med, 358, 1966
Cited by
Sorted by citations
Items 201–300 of 393
Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study
Du, Y., Ter‐Minassian, M., Brais, L. K., Brooks, N. V., Waldron, A., Chan, J. A., Lin, X., Kraft, P. L., Christiani, D. C., & Kulke, M. H. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0171 · Cited by 20
The Genetic Landscape of Pheochromocytomas and Paragangliomas: Somatic Mutations Take Center Stage
Dahia, P. L. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2191 · Cited by 20
You, M., Fu, M., Shen, Z., Feng, Y., Zhang, L., Zhu, X., Zhuang, Z., Mao, Y. Q., & Hua, W. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2356942 · Cited by 20
Self-citationThe Evaluation and Treatment of Endocrine Forms of Hypertension
Velasco, A., & Vongpatanasin, W. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0528-x · Cited by 19
Pheochromocytomas and Paragangliomas
Guo, Z., & Lloyd, R. V. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000086 · Cited by 19
Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?
Fishbein, L. M. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1184-y · Cited by 19
Integration and Visualization of Regulatory Elements and Variations of the EPAS1 Gene in Human
Kristan, A., Debeljak, N., & Kunej, T. (2021) · Genes · doi:10.3390/genes12111793 · Cited by 23
Fliedner, S. M. J., Shankavaram, U. T., Marzouca, G., ELKAHLOUN, A. G., Jochmanová, I., Därr, R., Linehan, W. M., Timmers, H. J. L. M., Tischler, A. S., Papaspyrou, K., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.008 · Cited by 20
Self-citationGenetic and clinical aspects of paediatric pheochromocytomas and paragangliomas
Petenuci, J., Guimaraes, A. G., Fagundes, G. F. C., Benedetti, A. F. F., Afonso, A. C. F., Pereira, M. A. A., Zerbini, M. C. N., Siqueira, S. A. C., Yamauchi, F. I., Soares, S. C., et al. (2021) · Clinical Endocrinology · doi:10.1111/cen.14467 · Cited by 18
Wang, Y., Abu-Asab, M. S., Shen, D., Zhuang, Z., Chew, E. Y., & Chan, C. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2660-0 · Cited by 18
Self-citationRapid Cardiovascular Response to Belzutifan in HIF2A -Mediated Paraganglioma
Alkaissi, H. R., Nazari, M. A., Vanova, K. H., Uher, O., Gordon, C. M., Talvacchio, S. K., Diachenko, N., Mukvich, O. M., Wang, H., Glod, J. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2409427 · Cited by 17
Self-citationMartinelli, S., Riverso, M., Mello, T., Amore, F., Parri, M., Simeone, I., Mannelli, M., Maggi, M., & Rapizzi, E. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111594 · Cited by 17
HIF2α Promotes Cancer Metastasis through TCF7L2-Dependent Fatty Acid Synthesis in ccRCC
Shi, J., Lv, Q., Miao, D., Xiong, Z., Wei, Z., Wu, S., Tan, D., Wang, K., & Zhang, X. (2024) · Research · doi:10.34133/research.0322 · Cited by 19
Somatic and germline mutations in NETs: Implications for their diagnosis and management
Minnetti, M., & Grossman, A. B. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.09.007 · Cited by 17
Moraitis, A. G., Martucci, V. L., & Pacák, K. (2014) · Endocrine Practice · doi:10.4158/ep13268.ra · Cited by 17
Tashi, T., Swierczek, S. I., & Prchal, J. T. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0414-x · Cited by 17
Self-citationClinical and molecular markers guide the genetics of pheochromocytoma and paraganglioma
Cascón, A., & Robledo, M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189141 · Cited by 16
Karaghiannis, V., Maric, D., Garrec, C., Maaziz, N., Buffet, A., Schmitt, L., Antunes, V., Airaud, F., Aral, B., Roy, A. L., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.281698 · Cited by 17
Pacak–Zhuang syndrome: a model providing new insights into tumor syndromes
Rosenblum, J. S., Wang, H., Nazari, M. A., Zhuang, Z., & Pacák, K. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0050 · Cited by 16
Self-citationDevelopmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma
Eckardt, L., Prange‐Barczynska, M., Hodson, E. J., Fielding, J. W., Cheng, X., Lima, J. D. C. C., Kurlekar, S., Douglas, G., Ratcliffe, P. J., & Bishop, T. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0211 · Cited by 16
Mallik, N., Das, R., Malhotra, P., & Sharma, P. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13632 · Cited by 16
Recent progress in molecular classification of phaeochromocytoma and paraganglioma
Boehm, E., Gill, A. J., Clifton-Bligh, R. J., & Tothill, R. W. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101939 · Cited by 15
Alkaissi, H. R., Talvacchio, S. K., Derkyi, A., Gubbi, S., Pappo, A. S., Gordon, C. M., Glod, J. W., Zhuang, Z., & Pacák, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.204 · Cited by 15
Self-citationMonteagudo, M., Calsina, B., Salazar-Hidalgo, M. E., Martínez‐Montes, Á. M., Piñeiro-Yáñez, E., Caleiras, E. J., Martín, M. C., Rodríguez, S., Letón, R., Gil, E., et al. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101931 · Cited by 15
Choi, H., Gillespie, D. L., Berg, S., Rice, C., Couldwell, S., Gu, J., Colman, H., Jensen, R. L., & Huang, E. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125125 · Cited by 15
Neuraxial dysraphism in EPAS1- associated syndrome due to improper mesenchymal transition
Rosenblum, J. S., Cappadona, A. J., Argersinger, D. P., Pang, Y. K., Wang, H., Nazari, M. A., Munasinghe, J., Donahue, D., Jha, A., Smirniotopoulos, J. G., et al. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000414 · Cited by 15
Self-citationHypoxia signaling pathway: A central mediator in endocrine tumors
Watts, D., Jaykar, M. T., Bechmann, N., & Wielockx, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1103075 · Cited by 15
Zhong, X., Su, T., Yang, Y., Ye, L., Jiang, L., Qi, Y., Xie, J., Jiang, Y., Zhou, W., Zhang, C., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad149 · Cited by 15
Parab, S., Setten, E., Astanina, E., Bussolino, F., & Doronzo, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108418 · Cited by 15
Paragangliomas Arising in the Head and Neck
Williams, M. D., & Rich, T. A. (2014) · Surgical pathology clinics · doi:10.1016/j.path.2014.08.007 · Cited by 15
Else, T. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0221 · Cited by 15
Liu, Q., Wang, Y., Tong, D., Liu, G., Yuan, W., Zhang, J., Ye, J., Zhang, Y., Yuan, G., Feng, Q.-X., et al. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9469-4 · Cited by 15
Mitochondrial complex II regulates a distinct oxygen sensing mechanism in monocytes
Sharma, S., Wang, J., Gomez, E. C., Taggart, R. T., & Baysal, B. E. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx041 · Cited by 16
Roszko, K. L., Brown, S. M., Pang, Y. K., Huynh, T., Zhuang, Z., Pacák, K., & Collins, M. T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4195 · Cited by 15
Self-citationArenillas, C., Celada, L., Ruiz-Cantador, J., Calsina, B., Datta, D., García‐Galea, E., Fasani, R., Moreno-Cárdenas, A. B., Alba‐Linares, J. J., Miranda, B., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0943 · Cited by 14
Pheochromocytoma: When to search a germline defect?
Buffet, A., Burnichon, N., Amar, L., & Gimenez‐Roqueplo, A. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.003 · Cited by 14
Chiari Malformation Type 1 in EPAS1-Associated Syndrome
Rosenblum, J. S., Maggio, D. M., Pang, Y. K., Nazari, M. A., Gonzales, M. K., Lechan, R. M., Smirniotopoulos, J. G., Zhuang, Z., Pacák, K., & Heiss, J. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112819 · Cited by 14
Self-citationFunctional significance of germline EPAS1 variants
Dwight, T., Kim, E., Bastard, K., Benn, D. E., Eisenhofer, G., Richter, S., Mannelli, M., Rapizzi, E., Prejbisz, A., Pęczkowska, M., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0280 · Cited by 15
Dötsch, A., Eisele, L., Rabeling, M., Rump, K., Walstein, K., Bick, A., Cox, L., Engler, A., Bachmann, H. S., Jöckel, K., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061266 · Cited by 14
Therapies targeting the signal pathways of pheochromocytoma and paraganglioma
Liu, Y., Liu, L., & Zhu, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s219056 · Cited by 14
15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
Mannelli, M., Rapizzi, E., Fucci, R., Canu, L., Ercolino, T., Luconi, M., & Young, W. F. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0215 · Cited by 15
Deficiency in PHD2-mediated hydroxylation of HIF2α underlies Pacak-Zhuang syndrome
Ferens, F. G., Taber, C. C., Stuart, S. E., Hubert, M., Tarade, D., Lee, J. E., & Ohh, M. (2024) · Communications Biology · doi:10.1038/s42003-024-05904-4 · Cited by 14
Crona, J., Ljungström, V., Welin, S., Walz, M. K., Hellman, P., & Björklund, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133210 · Cited by 13
Pereira, B. D., Silva, T., Bernardo, A. T., César, R., Luíz, H. V., Pacák, K., & Mota‐Vieira, L. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8470642 · Cited by 13
Zhao, B., Zhou, Y., Zhao, Y., Zhao, Y., Wu, X., Bi, Y., Luo, Y., Ji, Z., & Rong, S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00165 · Cited by 13
Congenital and evolutionary modulations of hypoxia sensing and their erythroid phenotype
Tashi, T., Song, J., & Prchal, J. T. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.12.001 · Cited by 12
Self-citationSomatic EPAS1 Variants in Pheochromocytoma and Paraganglioma in Patients With Sickle Cell Disease
White, G., Nonaka, D., Chung, T., Oakey, R. J., & Izatt, L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad311 · Cited by 12
Genetics of Pheochromocytoma and Paraganglioma
Pereira, B. D., Luíz, H. V., Ferreira, A. G., & Portugal, J. (2019) · Codon Publications eBooks · doi:10.15586/paraganglioma.2019.ch1 · Cited by 12
Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome
Dmitriev, P., Wang, H., Rosenblum, J. S., Prodanov, T., Cui, J., Pappo, A. S., Gilbert, M. R., Lutty, G. A., Chan, C., Chew, E. Y., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.5244 · Cited by 12
Self-citationHypoxia Signaling and Circadian Disruption in and by Pheochromocytoma
Tabebi, M., Söderkvist, P., & Jensen, L. D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00612 · Cited by 12
Chen, H., Zhu, W., Li, X., Xue, L., Wang, Z., & Wu, H. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2355-0 · Cited by 11
MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours
Crona, J., Maharjan, R., Verdugo, A. D., Stalberg, P. L. H., Granberg, D. O., Hellman, P., & Björklund, P. (2013) · Familial Cancer · doi:10.1007/s10689-013-9666-3 · Cited by 11
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 11
Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations
Smestad, J. A., & Maher, L. J., III (2019) · BMC Cancer · doi:10.1186/s12885-019-5813-z · Cited by 11
Bechmann, N., Rosenblum, J. S., & Alzahrani, A. S. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101955 · Cited by 10
Xie, H., Ma, K., Zhang, J., Hong, B., Zhou, J., Li, L., Zhang, K., Gong, K., & Cai, L. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106336 · Cited by 10
Phospho‐m TOR is not upregulated in metastatic SDHB paragangliomas
Ghayee, H. K., Giubellino, A., Click, A., Kapur, P., Christie, A. L., Xie, X., Martucci, V. L., Shay, J. W., Souza, R. F., & Pacák, K. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12127 · Cited by 10
Recognizing hypoxia in phaeochromocytomas and paragangliomas
Dahia, P. L. M., & Toledo, R. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0324-1 · Cited by 10
Kamilaris, C. D. C., Faucz, F. R., Andriessen, V. C., Nilubol, N., Lee, C. R., Ahlman, M. A., Hannah‐Shmouni, F., & Stratakis, C. A. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab007 · Cited by 10
Self-citationTsoli, M., Daskalakis, K., Kassi, E. N., Kaltsas, G., & Tsolakis, A. V. (2021) · Biology · doi:10.3390/biology10070580 · Cited by 10
Jochmanová, I., & Lazúrová, I. (2014) · Biomedical Papers · doi:10.5507/bp.2014.021 · Cited by 10
Multiplicity of Hormone-Secreting Tumors: Common Themes About Cause, Expression, and Management
Marx, S. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1511 · Cited by 9
Urbini, M., Nannini, M., Astolfi, A., Indio, V., Vicennati, V., Luca, M. D., Tarantino, G., Corso, F., Saponara, M., Gatto, L., et al. (2018) · International Journal of Genomics · doi:10.1155/2018/6582014 · Cited by 9
Genetics of the hypoxia-inducible factors in human cancers
Tanimoto, K. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.035 · Cited by 10
Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma
Karakaya, S., Gunnesson, L., Elias, E., Salvo, P. M., Robledo, M., Nilsson, O., Wängberg, B., Abel, F., Påhlman, S., Muth, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38606-8 · Cited by 8
SomaticIDH1Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas
Li, M., He, Y., Pang, Y., Zhang, J., Feng, Y. Y., He, Y., Xu, X., Wei, Y., Zhong, D., Deng, W., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac653 · Cited by 8
Polycythemia Secondary to Renal Hemangioblastoma: A Case Report and Literature Review
Lee, Y., Cheng, S. M., Hwang, D., Chiu, Y., & Chou, Y. (2023) · International Journal of Surgical Pathology · doi:10.1177/10668969231171133 · Cited by 8
Pheochromocytoma and paraganglioma in children and adolescents
Stachowicz‐Stencel, T., Pasikowska, N., & Synakiewicz, A. (2023) · Acta Biochimica Polonica · doi:10.18388/abp.2020_6955 · Cited by 8
Phaeochromocytoma and paraganglioma: next-generation sequencing and evolving Mendelian syndromes
Maher, E. R. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-4-440 · Cited by 8
HIF2 and endocrine neoplasia: an evolving story
Maher, E. R. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0146 · Cited by 8
Algorithmic evaluation of hereditary erythrocytosis: Pathways and caveats
Oliveira, J. L. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13019 · Cited by 8
Expression and Variations in EPAS1 Associated with Oxygen Metabolism in Sheep
Xi, Q., Zhao, F., Hu, J., Wang, J., Liu, X., Dang, P., Luo, Y., & Li, S. (2022) · Genes · doi:10.3390/genes13101871 · Cited by 7
EPAS1-related pheochromocytoma/paraganglioma
Alzahrani, A. S., Alswailem, M. M., Buffet, A., Alghamdi, B., Alobaid, L. A., Alsagheir, O., Al‐Hindi, H., & Pacák, K. (2024) · Endocrine Related Cancer · doi:10.1530/erc-23-0303 · Cited by 8
Distinct Stress Regulators in the CRL Family: Emerging Roles of F‐Box Proteins
Hwang, J., Lauinger, L., & Kaiser, P. (2025) · BioEssays · doi:10.1002/bies.202400249 · Cited by 7
Clinical manifestations of Pacak‐Zhuang syndrome in a male pediatric patient
Abdallah, A., Pappo, A. S., Reiss, U. M., Shulkin, B. L., Zhuang, Z., Pacák, K., & Bahrami, A. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28096 · Cited by 7
Self-citationEPAS1 ‐mutated paragangliomas associated with haemoglobin disorders
Mancini, M., Buffet, A., Porte, B., Amar, L., Lussey‐Lepoutre, C., Crinière, L., Baudin, É., Méatchi, T., Gimenez‐Roqueplo, A., Favier, J., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19278 · Cited by 7
An Update on the Histology of Pheochromocytomas: How Does it Relate to Genetics?
Oudijk, L., Gaal, J., Koopman, K., & de Krijger, R. R. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0672-1266 · Cited by 7
Bernardo‐Castiñeira, C., Sáenz‐de‐Santa‐María, I., Valdés, N., Astudillo, A., Balbı́n, M., Pitiot, A. S., Jiménez‐Fonseca, P., Scola, B., Tena, I., Molina‐Garrido, M., et al. (2018) · Head & Neck · doi:10.1002/hed.25386 · Cited by 7
Jögi, A. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_4 · Cited by 7
Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism
Hong, C. S., Yang, C., & Zhuang, Z. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.22 · Cited by 7
Self-citationZhang, M. L., Meredith, D. M., Bellizzi, A. M., Nowak, J. A., & Papke, D. J. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04167-6 · Cited by 6
AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2α SIGNALING
Isaacson, B. B., Bullova, P., Frone, M. N., Click, A., Hamplová, B., Rabaglia, J. L., Woodruff, S. L., Nwariaku, F. E., Kathuria, A., Pacák, K., et al. (2015) · Endocrine Practice · doi:10.4158/ep15889.or · Cited by 6
Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy
Stampone, E., Bencivenga, D., Capellupo, M. C., Roberti, D., Tartaglione, I., Perrotta, S., Ragione, F. D., & Borriello, A. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04852-2 · Cited by 6
Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2α mutation: A case report
Abdullah, A. E., Guérin, C., Impériale, A., Barlier, A., Battini, S., Pertuit, M., Roche, P., Essamet, W., Vaisse, B., Pacák, K., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5599 · Cited by 6
Gangliocytic Paraganglioma: a Diagnostic Pitfall of Rare Neuroendocrine Tumor
Okubo, Y. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9481-8 · Cited by 6
A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia
Yu, J., Shi, X., Yang, C., Bullova, P., Hong, C. S., Nesvick, C. L., Dmitriev, P., Pacák, K., Zhuang, Z., Cao, H., et al. (2020) · Aging · doi:10.18632/aging.102967 · Cited by 6
Self-citationParagangliomas in Carney–Stratakis Syndrome
Khurana, A., Mei, L., Faber, A. C., Smith, S. C., & Boikos, S. A. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0918-8340 · Cited by 6
Hypoxia-inducible factors link inflammation and lipid metabolism in atherosclerotic macrophages
Park, K. S., Ko, Y. J., & Choi, J.-H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1765661 · Cited by 5
Freitas-Castro, F., & Almeida, M. Q. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101922 · Cited by 5
Sanceau, J., Westbrook, R., & Favier, J. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.101772 · Cited by 5
Heritable and Syndromic Pheochromocytoma and Paraganglioma
Kopp, P. A. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-77048-2_4 · Cited by 5
Regulatory variation: an emerging vantage point for cancer biology
Li, L., Lorzadeh, A., & Hirst, M. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1250 · Cited by 5
Pacák, K., Timmers, H. J. L. M., & Eisenhofer, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00110-4 · Cited by 5
Evolving Clinical Presentation and Assessment of Pheochromocytoma: A Review
MERCADO-ASIS, L. B., Siao, R. M., & Amba, N. F. (2017) · Journal of Medicine University of Santo Tomas · doi:10.35460/2546-1621.2017-0050 · Cited by 5
Pheochromocytoma and multiple endocrine neoplasia syndromes
Waguespack, S. G., & Ying, A. K. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00023-8 · Cited by 5
The clinical landscape of HIF2α inhibitors in oncology
Saad, E., Machaalani, M., McDermott, D. F., & Choueiri, T. K. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01145-y · Cited by 4
Head and neck paraganglioma in Pacak-Zhuang syndrome
Rosenblum, J. S., Cole, Y., Dang, D. D., Lookian, P. P., Alkaissi, H. R., Patel, M., Cappadona, A. J., Jha, A., Edwards, N. A., Donahue, D., et al. (2025) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf001 · Cited by 4
Self-citationTashi, T., & Prchal, J. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801368-7.00012-0 · Cited by 4
Self-citationDong, X., Su, X., Yu, J., Liu, J., Shi, X., Pan, Q., Yang, J., Chen, J., Li, L., & Cao, H. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.11.011 · Cited by 5
123I‐metaiodobenzylguanidine radio‐guided navigation surgery for multiple recurrent paragangliomas
Nagano, Y., Inoue, M., Uchida, K., Otake, K., & Kusunoki, M. (2020) · Pediatrics International · doi:10.1111/ped.14093 · Cited by 4
Metadata
- Authors
- Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., Popovic, V., Stratakis, C. A., Prchal, J. T., & Pacak, K.
- Affiliations
- National Institutes of Health (US)
- National Institute of Neurological Disorders and Stroke (US)
- Veterans Health Administration (US)
- National Cancer Institute (MY)
- National Cancer Institute (UA)
- University of Belgrade (RS)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of Utah (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-09-06
- Volume
- 367
- Issue
- 10
- Pages
- 922-930
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3432945
- OpenAlex
- W2142033642
- Cited by
- 397
- References
- 26
- Citations by year
- 2026: 22 · 2025: 12 · 2024: 22 · 2023: 18 · 2022: 20 · 2021: 29 · 2020: 24 · 2019: 24 · 2018: 32 · 2017: 43 · 2016: 27 · 2015: 31 · 2014: 47 · 2013: 42 · 2012: 2
- FWCI
- 39.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P01CA108671)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD008735)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- HIF-2α, paraganglioma, polycythemia, somatostatinoma, gain-of-function mutations, protein half-life, prolyl hydroxylation, VHL, succinate dehydrogenase, pheochromocytoma
- MeSH terms
- Abdominal Neoplasms, Endothelial PAS Domain-Containing Protein 1, Adolescent, Adrenal Gland Neoplasms, Adult, DNA Mutational Analysis, Female, Humans, Hydroxylation, Mutation, Pancreatic Neoplasms, Paraganglioma, Polycythemia, Somatostatinoma, Transcription, Genetic, Up-Regulation, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
